Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL29685154 | 0.95 | TSHR (0.55) | TSHRALDH1A1KDM4EGLAGAA | |
| Sulfuric Acid SCHEMBL29684657 | 0.94 | TSHR (0.53) | TSHRALDH1A1KDM4EGLAGAA | |
| SCHEMBL28231556 | 0.93 | TSHR (0.56) | TSHRALDH1A1KDM4EGLAGAA | |
| SCHEMBL29684786 | 0.90 | TSHR (0.50) | TSHRALDH1A1KDM4EGLAGAA | |
| SCHEMBL1819502 | 0.89 | TSHR (0.49) | TSHRALDH1A1KDM4EGLAGAA | |
| SCHEMBL2435688 | 0.89 | ALDH1A1 (0.54) | TSHRALDH1A1KDM4EGLAGAA | |
| Gluconic Acid SCHEMBL29684835 | 0.83 | TSHR (0.44) | TSHRALDH1A1KDM4EGLAGAA | |
| SCHEMBL29684863 | 0.83 | ALDH1A1 (0.47) | TSHRALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL4405073 | 0.78 | ALDH1A1 (0.50) | TSHRALDH1A1KDM4EGLAGAA | |
| SCHEMBL14562932 | 0.78 | ALDH1A1 (0.50) | TSHRALDH1A1KDM4EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024192470-A1 | METHOD OF TREATING GLIOBLASTOMA OR OTHER CANCERS EXPRESSING P75 NEUROTROPHIN RECEPTOR | THE UNIVERSITY OF NEWCASTLE (AU) | 2024-09-26 | — | — | WO | disclosed |
| US-20220162177-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. | 2022-05-26 | — | — | US | disclosed |
| EP-2498782-B1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX INC (US) | 2019-01-09 | — | — | EP | disclosed |
| CN-108383804-A | The crystal form of neurotrophin simulated compound and its salt | 特罗菲克斯制药股份有限公司 | 2018-08-10 | — | — | CN | disclosed |
| CN-104761515-B | The crystal formation of neurotrophin simulated compound and its salt | 特罗菲克斯制药股份有限公司 | 2018-03-09 | — | — | CN | disclosed |
| WO-2012167869-A1 | AMINO LIPIDS, THEIR SYNTHESIS AND USES THEREOF | Karlsruher Institut für Technologie (DE) | 2012-12-13 | — | — | WO | disclosed |
| EP-2403839-A2 | NEUROTROPHIN MIMETICS AND USES THEREOF | The University of North Carolina At Chapel Hill (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2011066544-A2 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | PHARMATROPHIX, INC. (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162177-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | BDNF, NGF, NTRK2 | TSHR 971/4885ALDH1A1 4364/4885KDM4E 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.